title: [The clinical significance of determining the HLA-DR4 antigen in patients with breast cancer].
abstract: A study of HLA phenotype in 151 cases of breast cancer showed an increased occurrence of DR4 antigen (46.8%) as compared to general population (16.3%). Some clinical parameters of DR4-positive and DR4-negative patients were compared. Estradiol receptor-negative tumor was observed in 40% of DR4-positive patients and only in 18.5% of estradiol receptor-negative ones. DR4 positivity was associated with poorer prognosis.
authors.forename: L M
authors.initials: LM
authors.lastname: Iarygin
authors.forename: V S
authors.initials: VS
authors.lastname: Malyshev
authors.forename: I S
authors.initials: IS
authors.lastname: Polianskaia
authors.forename: L E
authors.initials: LE
authors.lastname: Denisov
authors.forename: Iu I
authors.initials: IuI
authors.lastname: Zimin
authors.forename: P L
authors.initials: PL
authors.lastname: Alekseeva
authors.forename: N V
authors.initials: NV
authors.lastname: Khotchenkova
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000737:chemistry / Q000276:immunology*; D005260:Female; D015804:HLA-DR4 Antigen / Q000032:analysis*; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
chemical_list: D015804:HLA-DR4 Antigen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
vernacular_title: Klinicheskoe znachenie opredeleniia antigena HLA-DR4 u bol'nykh rakom molochnoĭ zhelezy.